OZGUR SAHIN LAB – Molecular Mechanisms of Drug Resistance and Metastasis

Our Lab moved to the Department of Biochemistry & Molecular Biology and Hollings Cancer Center at MUSC!

Posted onMay 4, 2022May 4, 2022Leave a comment

Dr. Sahin has recently accepted a Professor and SmartState Endowed Chair position at the Dept. of Biochemistry & Molecular Biology and Hollings Cancer Center at Medical University of South Carolina. Starting May 1, our lab is located at HO703 at Read More …

Our new R01 grant is funded by the NIH/NCI

Posted onDecember 19, 2021January 26, 2022Leave a comment

This 5-year grant will address the mechanisms of resistance to chemotherapy in highly aggressive breast cancers using cutting-edge methodologies, including testing our recently developed LOX inhibitors. NEW positions are available for highly motivated postdocs and graduate students.

Dr. Sahin receives highly prestigious Mary Kay Ash Foundation grant

Posted onDecember 3, 2021December 3, 2021Leave a comment

This work aims to enhance the efficacy of antibody-drug conjugate (ADC) therapy in aggressive breast cancer. Here is the press release: https://marykayashfoundation.org/what-we-do/cancer-research/grant-recipients/

A NEW postdoc position is immediately available in our lab

Posted onAugust 12, 2021September 18, 2021Leave a comment

If you are interested in working at the intersection of mechanisms of drug resistance, metastasis and drug discovery, please apply via: https://www.nature.com/naturecareers/job/postdoctoral-fellow-in-cancer-research-university-of-south-carolina-columbia-sc-746191

Our R01 grant is funded by the NIH/NCI

Posted onAugust 12, 2021January 25, 2022Leave a comment

Our R01 grant aiming at blocking tumor growth and metastasis in highly aggressive breast cancers has been funded. In this exciting project, we will target highly aggressive breast cancers with our newly developed inhibitor.

A postdoctoral research fellow position is immediately available in our lab

Posted onMay 3, 2021May 15, 2021Leave a comment

Details of the position and how to apply are here.

Our collaborative paper with Halozyme, Inc has been published in Cancer Research

Posted onMay 3, 2021May 14, 2021Leave a comment

This study introduces endogenous ADA2 expression as a prognostic factor and PEGADA2 as a novel immunotherapy for cancer. Read the article here.

Dr. Sahin gave a talk on “Targeting LOX in chemoresistance and developing novel LOX inhibitors” at the ACS Mini Symposium

Posted onFebruary 21, 2021February 21, 2021Leave a comment

Dr. Sahin co-organized a Mini Symposium with Dr. Taru Muranen (Dana-Farber Cancer Institute) and Rebeca San Martin (University of Tennessee, Knoxville) which was hosted by Joe Cotter from the American Cancer Society – February 17, 2021. The Mini Symposium was Read More …

Dr. Sahin presents “From mechanisms of resistance to drug discovery” at IBG Seminer Series

Posted onFebruary 21, 2021February 21, 2021Leave a comment

Dr. Sahin presented our recent work on how we take genome/transcriptome-wide approaches to identify regulators of drug resistance, identify mechanisms of resistance and develop novel drug candidates on Feb 12, 2021 at the Seminar Series of Izmir Biomedicine and Genome Read More …

Dr. Sahin presents a “Lightning Talk” at AACR Virtual Special Congress

Posted onJanuary 20, 2021January 22, 2021Leave a comment

AACR Virtual Special Congress, “The Evolving Tumor Microenvironment in Cancer Progression; Mechanisms and Emerging Therapeutic Opportunities” – January 11-12, 2021, brought together experts from diverse fields to thoroughly explore and discuss the topic. Dr. Sahin gave a “Lightning Talk” on Read More …